Background Renal osteodystrophy is one of the commonest complications of chronic renal failure. It may have a severe impact on the quality of life of patients on maintenance dialysis therapy. Besides post-menopausal w...Background Renal osteodystrophy is one of the commonest complications of chronic renal failure. It may have a severe impact on the quality of life of patients on maintenance dialysis therapy. Besides post-menopausal women and elderly people, the dialysis patients are another high risk group. But at present, there is no research on how to prevent osteoporosis in maintenance dialysis patients. This study was conducted to observe the bone density of maintenance dialysis patients and to evaluate the clinical outcomes and safety of different administration dosage of salmon calcitonin to prevent osteoporosis in maintenance dialysis patients. Methods One hundred and forty-eight patients on maintenance dialysis were involved in the 12-month, randomized, controlled trial. Fifty patients （experiment I group） received subcutaneous injection of salmon calcitonin （50 U） three times a week for 12 months. Fifty patients （experiment II group） received subcutaneous injection of salmon calcitonin （100 U） three times a week for 12 months. At the same time, both of them received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 pg qn for 12 months. The control group only received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 μg qn for 12 months. The levels of bone mass density （BMD） of the lumbar spine and femoral neck, serum intact parathyroid hormone （iPTH）, osteocalcin （OC）, calcium, phosphorus, alkaline phosphatase （ALP） were assessed at baseline and then again after 3, 6 and 12 months of treatment. Results The values of BMD at the lumbar spine and femoral neck before the treatment were not significantly different from those 3, 6, and 12 months after the treatment in trial groups I and II （all P 〉0.05） and there were no significant differences in the BMD values at different time points between trial groups I and II. In the control group, the BMD values at the lumbar spine and femoral neck 3, 6, and 12 months after the beginning of trial were significantly lower than those before展开更多
文摘Background Renal osteodystrophy is one of the commonest complications of chronic renal failure. It may have a severe impact on the quality of life of patients on maintenance dialysis therapy. Besides post-menopausal women and elderly people, the dialysis patients are another high risk group. But at present, there is no research on how to prevent osteoporosis in maintenance dialysis patients. This study was conducted to observe the bone density of maintenance dialysis patients and to evaluate the clinical outcomes and safety of different administration dosage of salmon calcitonin to prevent osteoporosis in maintenance dialysis patients. Methods One hundred and forty-eight patients on maintenance dialysis were involved in the 12-month, randomized, controlled trial. Fifty patients （experiment I group） received subcutaneous injection of salmon calcitonin （50 U） three times a week for 12 months. Fifty patients （experiment II group） received subcutaneous injection of salmon calcitonin （100 U） three times a week for 12 months. At the same time, both of them received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 pg qn for 12 months. The control group only received oral calcium carbonate 1500 mg tid and rocaltrol 0.25 μg qn for 12 months. The levels of bone mass density （BMD） of the lumbar spine and femoral neck, serum intact parathyroid hormone （iPTH）, osteocalcin （OC）, calcium, phosphorus, alkaline phosphatase （ALP） were assessed at baseline and then again after 3, 6 and 12 months of treatment. Results The values of BMD at the lumbar spine and femoral neck before the treatment were not significantly different from those 3, 6, and 12 months after the treatment in trial groups I and II （all P 〉0.05） and there were no significant differences in the BMD values at different time points between trial groups I and II. In the control group, the BMD values at the lumbar spine and femoral neck 3, 6, and 12 months after the beginning of trial were significantly lower than those before
文摘目的:测定早产儿25羟维生素D含量,探讨影响早产儿25羟维生素D含量的主要因素。方法 :选取2012年5月—2013年9月在无锡市妇幼保健院和无锡市第三人民医院出生、住院的新生儿,早产儿组50例,足月儿组50例,记录出生时的基本情况,根据不同目的将研究对象分为不同组别。采用酶联免疫法测定早产儿和足月儿25羟维生素D含量,用常规生化法测定钙、磷、碱性磷酸酶(alkaline phosphatase,ALP)值,定量超声技术测定骨密度(bone mineral density,BMD)值。结果:1出生时早产儿组25羟维生素D含量低于足月儿组,差异有统计学意义(P<0.01)。2按胎龄分组,A组(28周≤胎龄≤32周)新生儿血25羟维生素D含量均低于B组(32周<胎龄<37周)、C组(37周≤胎龄<39周)、D组(39周≤胎龄≤42周)(P均<0.01);按出生时体重分组,各体重组血25羟维生素D水平两两比较均有显著性差异(P均<0.01)。3早产儿组按孕母是否规律性补充维生素D或钙剂分成规律补充、不规律补充和未补充3组,3组之间血25羟维生素D水平两两比较均有显著性差异(P<0.05)。4早产儿出生时25羟维生素D含量与胎龄、出生体重呈正相关(P<0.05);足月儿出生时25羟维生素D含量与胎龄、性别、出生体重及出生方式均无显著相关(P>0.05)。5早产儿和足月儿出生时血钙、磷、ALP值均无显著性差异(P>0.05);早产儿组25羟维生素D与ALP呈显著性负相关(P<0.01);足月儿组25羟维生素D与ALP、钙、磷值均无显著性相关(P>0.05)。6早产儿和足月儿BMD有显著差异(P<0.01);早产儿组BMD与胎龄、出生体重、25羟维生素D呈正相关(P<0.05),与ALP呈负相关(P<0.05);足月儿组BMD与胎龄、25羟维生素D呈正相关(P<0.05)。结论:1早产儿出生时25羟维生素D含量明显低于足月儿;2早产儿出生时的胎龄、体重以及孕母在整个孕期中是否规律性补充维生素D制剂或钙剂是影响早产儿出生时25羟维生素D含量的主要因素。
